Is PT-141 (Bremelanotide) Legal in Michigan? How to Access It Legally
HealthRX.com
PT-141 is legal in Michigan only as prescription Vyleesi
See the public record for Bremelanotide
At a glance
- Federal status / FDA-approved as Vyleesi on June 21, 2019 (NDA 210557), prescription only [1][2]
- Approved use / premenopausal women with acquired, generalized HSDD [1]
- How it is taken / 1.75 mg subcutaneous autoinjector, as needed, at least 45 minutes before sexual activity [1]
- Michigan telehealth / a prescriber acting within scope may prescribe by telehealth, with follow-up duties [3]
- Research or compounded PT-141 / not FDA-approved; FDA does not verify safety, effectiveness or quality of compounded drugs [5]
What legal status does bremelanotide have in Michigan?
FDA approved bremelanotide as Vyleesi on June 21, 2019 under new drug application 210557 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), and it is dispensed by prescription only [1][2]. The clinical evidence includes two identical 24-week, randomized, double-blind, placebo-controlled trials in which 1,267 premenopausal women were randomized [6].
Michigan's telehealth provision applies to prescription drugs generally and does not name bremelanotide [3]. What the statute does set is who may issue the prescription. MCL 333.16285 allows a health professional providing a telehealth service to prescribe a drug when the professional is a prescriber acting within the scope of their practice [3]. It also requires the prescriber to give the patient a referral for other care, including emergency services, that is geographically accessible when the prescriber considers it medically necessary, and to be available (or have someone acting under their delegation be available) for follow-up care or a referral for it [3]. Controlled substances have their own additional requirements in that section [3].
How a legal prescription actually happens
The indication. The label describes acquired, generalized HSDD as low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug [1]. Acquired means the problem developed in someone who previously had no difficulty with desire; generalized means it occurs regardless of stimulation, situation or partner [1].
The prescriber. Under MCL 333.16285, a prescriber working within the scope of their practice can write the prescription after a telehealth visit, and takes on the follow-up obligations that come with any telehealth prescription [3].
The cardiovascular screen. The label contraindicates Vyleesi in people with uncontrolled hypertension or known cardiovascular disease, says to consider the patient's cardiovascular risk and ensure blood pressure is well controlled before starting and periodically during treatment, and does not recommend it for patients at high risk for cardiovascular disease [1].
The product dispensed. Vyleesi is the FDA-approved prescription product [1].
Questions worth asking
Who the label covers, and who it does not
Vyleesi is not indicated for the treatment of HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance [1].
Compounded and research-use PT-141
What is sold as "PT-141" in compounded or research-use form is not Vyleesi and is not an FDA-approved drug [4][1]. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [5].
Bremelanotide does not appear on FDA's list of bulk drug substances that may present significant safety risks [7], and it appears in no category on FDA's bulk-substance lists [8]. It is also not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [9]. Absence from the safety-risk list is not the same as being on a list that permits compounding; bremelanotide is on neither [7][8].
FDA says that purchasing medicine online from unregulated, unlicensed sources can expose patients to poor-quality products, and it points consumers to BeSafeRx to check an online pharmacy before using it [5].
What the label says to expect
The most common adverse reaction is nausea, reported by 40.0% of Vyleesi-treated women versus 1.3% on placebo; 13% needed anti-nausea medicine and 8% stopped the trials because of it [1]. Pre-treating with 8 mg of oral ondansetron 30 minutes before the dose did not reduce nausea in a phase 4 study of 228 healthy women, and the label does not recommend it [1].
Each dose raises blood pressure and lowers heart rate transiently. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after the dose, with a heart rate reduction of up to 5 beats per minute and a return to baseline usually within 12 hours [1]. In a separate open-label study of 127 premenopausal women dosed daily for 8 days, the mean daytime increase was 1.9 mmHg systolic and 1.7 mmHg diastolic, with a mean heart rate decrease of 0.5 beats per minute [1].
Focal hyperpigmentation (darkening of the face, gums or breasts) was reported by 1% of patients receiving up to 8 doses a month in the placebo-controlled trials, versus none on placebo; risk is higher with darker skin and daily dosing, resolution was not confirmed in everyone, and the label says to consider discontinuing if it develops [1].
The label gives the dose as 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours; more than 8 doses a month is not recommended [1]. The label says to stop if there is no improvement after 8 weeks [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 (bremelanotide) legal in Michigan?
Can a Michigan prescriber order bremelanotide over telehealth?
Can men or postmenopausal women get bremelanotide on label?
Is compounded or research-use PT-141 legal in Michigan?
Who should not use Vyleesi according to the label?
What dose does the Vyleesi label specify?
References
Show all 9 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- MCL - Section 333.16285 - Michigan Legislature.
- Official web page.
- Compounding and the FDA: Questions and Answers | FDA.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.